Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : Reports More Positive Phase 3 Study Results for V114 Vaccine

10/20/2020 | 07:24am EDT

By Colin Kellaher

Merck & Co. on Tuesday reported positive results for its V114 investigational 15-valent pneumococcal conjugate vaccine in two additional phase 3 studies.

The Kenilworth, N.J., drug maker said V114 met its primary immunogenicity objectives and elicited a strong immune response for all 15 serotypes included in the vaccine, including 22F and 33F, the two serotypes targeted by V114 but not by the currently available 13-valent pneumococcal conjugate vaccine.

Merck said V114 was generally well tolerated in both studies, with a safety profile consistent with that observed in previously reported studies.

Merck in September said a pair of phase 3 studies evaluating V114 had met their primary immunogenicity objectives.

The company said its plans for global regulatory licensure applications, beginning with the U.S. Food and Drug Administration before the end of the year, remain on track.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

10-20-20 0723ET

All news about MERCK & CO., INC.
07:36aMERCKá : Says Phase 3 Trial Met Endpoints of Overall Survival, Progression-Free ..
MT
06:46aMERCKá : Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overa..
BU
05:17aMerck's Keytruda Meets Main Endpoints in Cervical-Cancer Study
DJ
04:24aASTRAZENECAá : Gets European Commission's Conditional Approval for Koselugo in P..
MT
02:31aASTRAZENECAá : Merck & Co. Win Conditional EU Nod for Rare Disease Drug in Child..
MT
06/21MERCKá : CONSOLIDATED STATEMENT OF INCOME - GAAP (Form 8-K)
PU
06/21MERCK & CO., INC.á : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
06/17MERCKá : Unveils Supply Deal With US Government for Investigational Therapy Moln..
MT
06/17MERCKá : to Participate in the Guggenheim Biopharma Strategy Series
BU
06/16MERCKá : Announces the Kenneth C. Frazier Award for Maternal Health Equity to Ac..
BU
More news
Financials (USD)
Sales 2021 48 173 M - -
Net income 2021 13 706 M - -
Net Debt 2021 11 622 M - -
P/E ratio 2021 14,7x
Yield 2021 3,41%
Capitalization 193 B 193 B -
EV / Sales 2021 4,25x
EV / Sales 2022 3,96x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 76,19 $
Average target price 95,45 $
Spread / Average Target 25,3%
EPS Revisions
Managers and Directors
NameTitle
Kenneth C. Frazier Chairman & Chief Executive Officer
Robert M. Davis President
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-6.17%194 335
JOHNSON & JOHNSON3.96%431 456
ROCHE HOLDING AG12.99%328 650
PFIZER, INC.7.61%220 661
NOVARTIS AG3.00%210 615
ABBVIE INC.7.05%202 639